Figure 3.

Platelet and leucocyte count during the course of treatment. (A) Platelet (blue curve) and leukocyte count (green curve) during the course of treatment. The graph illustrates a large decrease in leucocyte and platelet count 23 days after PRRT in combination with capecitabin/temzolomid. The results also exhibit a decline in platelet and leucocyte count after the administration of four cycles of PRRT, which rapidly increased subsequently, and stabilized during partial remission, with a decrease as the disease progressed. (B) Hemoglobin levels during the course of treatment. The graph illustrates a progressive decrease in hemoglobin levels after initial diagnosis resulting in chronic anemia. Despite a decrease in hemoglobin levels after four cycles of PRRT, the anemia may have been cancer-related, showing a decline with progressive disease. Subsequent to granulocyte-colony stimulating factor stimulation and the administration of erythrocyte concentrates during hospitalization in July 2019, hemoglobin levels normalized. PRRT, peptide receptor radionuclide therapy.